Inclusion Criteria:

          -  Subject must have advanced solid tumor that is not amenable to surgical resection or
             other approved therapeutic options that have demonstrated clinical benefit.

          -  Subject has adequate bone marrow, renal, hepatic and coagulation function.

          -  Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors
             (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens including
             but not limited to cancer antigen (CA-125) and prostate-specific antigen (PSA).

          -  Women of childbearing potential must have a negative serum pregnancy test at the
             screening visit and a negative urine pregnancy test at baseline prior to the first
             dose of study drug. Female subject considered not of childbearing potential must be
             documented as being surgically sterile or post-menopausal for at least 1 year. Women
             of childbearing potential and men must agree to use adequate contraception.

          -  Subjects in the combination therapy cohorts must meet the above inclusion criteria and
             be eligible to receive paclitaxel or FOLFIRI per most current prescribing information,
             or at the discretion of the Investigator. Subjects in the combination therapy cohorts
             who are to receive ABBV-181, an anti-PD1 antibody, must also meet other criteria
             described in the Protocol.

        Exclusion Criteria:

          -  Subject has received anticancer therapy including chemotherapy, radiation therapy,
             immunotherapy, biologic, or any investigational therapy within a period of 21 days or
             anti-cancer herbal therapy within 7 days prior to Cycle 1 Day 1 of ABT-165.

          -  Subject has uncontrolled metastases to the central nervous system (CNS).

          -  Subject has unresolved clinically significant toxicities from prior anticancer
             therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
             or higher.

          -  Subject has history (within previous 5 years) of clinically significant pulmonary
             hypertension, uncontrolled systemic hypertension or hypertensive crisis, symptomatic
             heart failure, cardiomyopathy, myocardial infarction, unstable/severe angina pectoris,
             cardiac arrhythmia requiring medication, coronary/peripheral artery bypass graft,
             aneurysm or aneurysm repair, angioplasty, cerebrovascular accident, transient ischemic
             attack or the left ventricular ejection fraction (LVEF) less than 50%.

          -  Subjects enrolled on the combination therapy phase must not meet the above exclusion
             criteria and must be eligible to receive paclitaxel or FOLFIRI per most current
             prescribing information, or at the discretion of the Investigator. Subjects receiving
             ABBV-181 must not meet other exclusion criteria described in the Protocol.